File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Book Chapter: Hong Kong experience

TitleHong Kong experience
Authors
KeywordsDiagnosis
Esophageal carcinoma
Treatment experience
Issue Date2015
PublisherSpringer
Citation
Hong Kong experience. In Nobutoshi Ando (Ed.), Esophageal Squamous Cell Carcinoma: Diagnosis and Treatment, p. 261-278. Tokyo: Springer, 2015 How to Cite?
AbstractEsophageal cancer is the sixth most common cancer in the world [1]. There has been a divergence of histological cell type between the East and West. In western countries, adenocarcinoma has increased dramatically in incidence in the past 30 years, closely related to rising prevalence of obesity, gastroesophageal reflux disease, and Barrett’s esophagus. In Asia, esophageal squamous cell carcinoma (ESCC) remains the predominant cell type; more than 80 % of esophageal cancer is squamous cell in origin. There has not been a convincing rise in incidence of true adenocarcinoma of the esophagus (Siewert type I) in Asia. In Hong Kong, ESCC accounts for more than 90 % of all esophageal cancers. In 2010, the Cancer Registry of Hong Kong identified esophageal cancer as the eighth leading cause of cancer deaths. The overall 5-year survival rate was disappointing at around 20 % only [2]. There has been advancement of technology in diagnosis, staging, and treatment of this highly lethal disease in the last few decades. In Hong Kong, more than 70 % of esophageal cancer patients are diagnosed at stage III/IV. Diagnosis at an earlier stage can improve the outcome and prognosis. Accurate staging allows optimal stage-directed therapeutic strategy. Multimodality treatment methods such as neoadjuvant chemotherapy or chemoradiation with surgery have gained popularity and outcomes have improved compared with surgical resection alone. The authors will summarize the treatment strategies and experience at The University of Hong Kong.
Persistent Identifierhttp://hdl.handle.net/10722/210962
ISBN

 

DC FieldValueLanguage
dc.contributor.authorTong, DKH-
dc.contributor.authorLaw, SYK-
dc.date.accessioned2015-06-23T06:01:31Z-
dc.date.available2015-06-23T06:01:31Z-
dc.date.issued2015-
dc.identifier.citationHong Kong experience. In Nobutoshi Ando (Ed.), Esophageal Squamous Cell Carcinoma: Diagnosis and Treatment, p. 261-278. Tokyo: Springer, 2015-
dc.identifier.isbn9784431549765-
dc.identifier.urihttp://hdl.handle.net/10722/210962-
dc.description.abstractEsophageal cancer is the sixth most common cancer in the world [1]. There has been a divergence of histological cell type between the East and West. In western countries, adenocarcinoma has increased dramatically in incidence in the past 30 years, closely related to rising prevalence of obesity, gastroesophageal reflux disease, and Barrett’s esophagus. In Asia, esophageal squamous cell carcinoma (ESCC) remains the predominant cell type; more than 80 % of esophageal cancer is squamous cell in origin. There has not been a convincing rise in incidence of true adenocarcinoma of the esophagus (Siewert type I) in Asia. In Hong Kong, ESCC accounts for more than 90 % of all esophageal cancers. In 2010, the Cancer Registry of Hong Kong identified esophageal cancer as the eighth leading cause of cancer deaths. The overall 5-year survival rate was disappointing at around 20 % only [2]. There has been advancement of technology in diagnosis, staging, and treatment of this highly lethal disease in the last few decades. In Hong Kong, more than 70 % of esophageal cancer patients are diagnosed at stage III/IV. Diagnosis at an earlier stage can improve the outcome and prognosis. Accurate staging allows optimal stage-directed therapeutic strategy. Multimodality treatment methods such as neoadjuvant chemotherapy or chemoradiation with surgery have gained popularity and outcomes have improved compared with surgical resection alone. The authors will summarize the treatment strategies and experience at The University of Hong Kong.-
dc.languageeng-
dc.publisherSpringer-
dc.relation.ispartofEsophageal Squamous Cell Carcinoma: Diagnosis and Treatment-
dc.subjectDiagnosis-
dc.subjectEsophageal carcinoma-
dc.subjectTreatment experience-
dc.titleHong Kong experience-
dc.typeBook_Chapter-
dc.identifier.emailTong, DKH: esodtong@hku.hk-
dc.identifier.emailLaw, SYK: slaw@hkucc.hku.hk-
dc.identifier.authorityLaw, SYK=rp00437-
dc.identifier.doi10.1007/978-4-431-54977-2_15-
dc.identifier.hkuros244178-
dc.identifier.spage261-
dc.identifier.epage278-
dc.publisher.placeTokyo-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats